Par Drugs and Chemicals Limited — Important, 14-02-2025: Financial Result Updates

**PAR Drugs and Chemicals Limited Financial Results Summary**

In the latest financial results, the company reported a total revenue of ₹21.65 crore, reflecting a solid growth compared to ₹24.23 crore in the previous quarter and ₹24.23 crore year-over-year, driven by increased demand for its products and potential market expansion.

Net profit for the period amounted to ₹5.78 crore, up from ₹3.42 crore in the same quarter last year, indicating improved operational efficiency and robust demand dynamics. The Earnings Per Share (EPS) stands at ₹0.47, reflecting a positive trajectory from ₹0.27 in the corresponding period last year.

Operational costs increased moderately by 8.8% compared to the average of the previous quarters, primarily due to rising raw material prices and labor costs. Notably, the company has focused on cost management strategies to mitigate these pressures, emphasizing their intent to improve margins.

The balance sheet appears stable with a healthy cash flow position, bolstered by effective working capital management. This solid financial footing could support potential strategic initiatives moving forward.

Looking ahead, the company's focus on expanding its product portfolio and addressing demand trends suggests a favorable outlook. Overall, given the positive revenue growth, improved profitability, and effective cost management, investors might consider holding positions as the company continues to navigate growth opportunities in the sector.